Dose-finding study of oral idarubicin and cyclophosphamide in first-line treatment of elderly patients with metastatic breast cancer.
Kurtz
J E
JE
Department of Onco-Hematology, Hôpitaux Universitaires de Strasbourg, France. jean-emmanuel.kurtz@chru-strasbourg.fr
Deplanque
G
G
Borel
C
C
Mathelin
C
C
Prévost
G
G
Poulin
G
G
Barats
J C
JC
Bergerat
J P
JP
Chapelle-Marcillac
I
I
Bardonnet
M
M
Dufour
P
P
D000284:Administration, Oral; D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage* / Q000009:adverse effects; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016001:Confidence Intervals; D003520:Cyclophosphamide / Q000008:administration & dosage; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage*; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011379:Prognosis; D012074:Remission Induction; D015996:Survival Rate; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D003520:Cyclophosphamide; D015255:Idarubicin